Home
NewsNewsMemphasys Felix Qatar IVF orders secure Hamad Medical Corporation as a reference customer, driving robust cartridge demand, accelerating widespread IVF adoption across the MENA region, and establishing crucial clinical credibility for future expansion.
Memphasys Felix Qatar IVF orders entered a commercial execution phase after Hamad Medical Corporation (HMC) began routine clinical purchasing of Felix™ cartridges in Qatar. HMC, the country’s largest public healthcare provider and leading IVF service, is now ordering approximately 100 cartridges per month, supporting close to 1,500 IVF cycles annually and creating a recurring institutional demand profile.
The agreement marks Memphasys’ first large-scale institutional customer in the Middle East and North Africa and follows CE Mark approval, which allows Felix™ to be used immediately across Qatar and other CE-recognised MENA markets. The deployment is being executed under Memphasys’ go-direct commercial strategy with distribution partner International Technical Legacy.
HMC’s projected annual usage of roughly 1,200 cartridges represents almost half of International Technical Legacy’s minimum annual commitment of 2,500 cartridges, significantly de-risking contracted volumes. This single institutional adoption also establishes a high-credibility reference point for Memphasys Felix Qatar IVF orders as the company targets broader uptake across the region’s estimated 350 IVF clinics.
Felix™ is positioned as an alternative to centrifugation-based sperm preparation, which can expose sperm cells to mechanical stress and DNA damage. The system uses a patented bioseparation process combining electrophoresis and size-exclusion membranes to isolate viable sperm with reduced cellular stress, faster laboratory workflows and more standardised results across operators.
Outside of Qatar, Memphasys has also received a follow-on order of 200 cartridges from International Technical Legacy (ITL), representing demand from clinics across the UAE and neighbouring regions. Memphasys is in late-stage commercial discussions with clinics in five other countries, looking to expand into those markets in the short-term.
Egypt will be another focus market for Memphasys expansion, with demand for IVF therapies expected to reach over USD 500 million. To continue supporting growth in the region, Memphasys’ A/Prof Hassan Bakos, Director of Clinical Partnerships and Growth, will undertake his second partner-funded visit to the region. He will be working with HMC to optimise usage, onboard clinics rapidly and meet with clinicians at a large ART conference taking place in Egypt.
Together, the HMC deployment and follow-on regional orders demonstrate that Felix™ is transitioning from evaluation to routine clinical use. The cartridge-based consumable model supports recurring revenue, while institutional adoption provides validation that extends beyond a single customer win.
Technology-Enabled Cryostorage is transforming fertility storage as Reprotech and TMRW combine expertise in digital specimen management and biorepository services. The partnership enhances scalability, safety, and efficiency while supporting clinics with advanced solutions. This strategic move positions the combined company to lead innovation and meet growing global demand in cryostorage services.
First AI-powered egg-freezing program has been initiated by Sunfish with an intent to get rid of uncertainty within the fertility preservation space, offering personalised insights and higher success predictability for women.
3billion has gone on to launch the Family Insight Test using WES and WGS analysis aimed at targeting couples who cannot get pregnant for no apparent reason, helping them discover hidden genetic factors affecting fertility.
Arbor Fertility™ with 8 locations in Missouri & Illinois has designed a streamlined patient-centred approach leading to Affordable, Accessible Fertility Care, making high-quality treatment available without financial burden.
BGI Genomics, a Chinese biotechnology company is working on AI-Powered Chromosome Screening Tools so as to accelerate and enhance IVF treatments in China, aiming to reduce genetic abnormalities and increase live birth outcomes.
Before taking a call on IVF, survey conducted in the U.S., UK, Ireland, and Canada suggests that people are looking for complete & less expensive options to treat root causes of infertility.
The Tennessee State Law could change how the embryos are handled at the time of treatment, thereby making the IVF clinic services in the state more expensive for patients seeking fertility care.
